We would like to invite you to the “Cystic Fibrosis Functional Genetics Training”, provided by prof. dr. Harm Tiddens and dr. Martina Wilke, both from the Erasmus Medical Center in Rotterdam.
The training will be organized for Belgian and Dutch physicians in order to discuss similarities and differences in the genetic approach of CF-patients.
The first training session took place on May 17. Based on feedback, this training was considered “A great lecture, about functional genetics” and is recommended to attend.
This second training session is organized for the persons who could not attend the first session, and will take place virtually on September 20, from 18:00 to 19:30.
Genetics of CF is central in this training and the following topics will be discussed in more detail:
As we would like to have an interactive training, we kindly ask you to install the Mentimeter app. This app will enable you to respond to questions during the training.
For your preparation, we also provide you with the publication of Farrell et al. 2017 "Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation".
Next to the theory of genetics, we want to encourage the discussion of case studies. If you have amongst your patient population an interesting case it would be great to discuss this within the group. Please let us know if this is the case and please forward this case before the 2 of September so prof. Tiddens and dr. Wilke can prepare accordingly.
The training has been compiled by the undersigned and made possible by Vertex Pharmaceuticals.
You can register for this training by replying to gert_devoer@vrtx.com. In case of questions about this training, please also reply to this message.
In NL this in-service training has been accredited by the NVK, VKGN and NVALT.
With kind regards,
Dr. Martina Wilke, Laboratory Specialist Clinical Genetics, ErasmusMC
Prof.dr. Harm Tiddens, Professor in Pediatric Pulmonology, ErasmusMC
Nathalie Klaykens, Vertex Pharmaceuticals
Edgar Janssen, Vertex Pharmaceuticals
Gert de Voer, Vertex Pharmaceuticals